Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung
cancer (NSCLC) Stage IIIB with pleural effusion OR Stage IV OR Recurrent disease
Bidimensionally measurable disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Karnofsky 50-100%
Life expectancy: Not specified Hematopoietic: WBC greater than 3,000/mm3 Absolute
neutrophil count at least 1,500/mm3 Platelet count greater than 100,000/mm3 Hepatic:
Bilirubin normal SGOT less than 2 times normal Renal: Creatinine no greater than 1.5 mg/dL
OR Creatinine clearance at least 50 mL/min BUN less than 1.5 times normal Cardiovascular:
No symptomatic congestive heart failure No unstable angina or myocardial infarction within
the past 6 months No evidence of heart block greater than first degree, bundle branch
block, or ventricular or supraventricular arrhythmia Other: No allergy to platinum
compounds or antiemetics appropriate for study No other uncontrolled illness No active or
ongoing infection No evidence of peripheral neuropathy by physical exam or history Not
pregnant or nursing Negative pregnancy test Fertile patients must use effective
contraception during and for 6 months after study

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy for advanced NSCLC At least 4 weeks since prior chemotherapy Endocrine
therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy Surgery:
Not specified Other: No other concurrent investigational agents No concurrent
antiretroviral therapy for HIV positive patients